

Marinomed programs at a glance


Business Development

October 2022



Marinomed at a glance

Lean, public company
with track record of
successfully inventing,
partnering and
marketing products
creating sustainable
value for patients and
stakeholders



Marinomed has built a proven track record

Successes in the therapeutic areas

Immunology (Marinosolv®)

- First **aqueous steroid solution**, all other major competitors are suspensions



- **Dose reduced by >85%** compared to originator
- Primary and secondary endpoint met in **successful clinical Phase III**
- **Patent protected**
- **Partnered**




Virology (Carragelose®)

- **Discovery** of the efficacy of Carragelose® against respiratory viruses
- Performance of a series of **clinical studies** to support the efficacy
- Generating sustainable **revenues and contribution margins**
- **Patent protected**
- Successful **partnering** in more than 40 countries across the globe; examples:



Strong pipeline for future growth




Tacrosolv (MAM-1003-1):

Highlights & strategy

- **Tacrolimus** is a **potent immunosuppressant** with a very low solubility in aqueous formulations
- The **goal** is to make it available for a multitude of **ophthalmic inflammatory diseases**
- Marinomed has developed a formulation with substantially **increased solubility** and bioavailability enabled by Marinosolv® technology
- Increased bioavailability enables a **reduction of dose** as **preclinically** demonstrated
- **Anti-inflammatory** activity **clinically** shown in model indication (allergic conjunctivitis)
- Significant **improvement of HSK (herpetic stromal keratitis) indicators** was shown in tacrolimus **add-on therapy** in a reference study

Partnering Strategy

- Looking for an experienced partner in ophthalmology for further clinical development in HSK or other relevant diseases
- Available for in-licensing
- IP protection (Marinosolv®) until 2036
- Classical license deal favored




Autoimmune Gastritis (MAM-1004-2):

Program highlights & strategy

- Autoimmune gastritis is an **inflammatory** disease of the stomach's mucosa leading to the destruction of parietal cells
- The **goal** is to develop the first medication for this **unmet medical need**
- Loss of parietal cells leads to a pH increase in the stomach
- Increased risk to develop **pernicious anemia** and **gastric tumors**
- “**Female disorder**” – women are more affected than men
- Difficult to diagnose due to diffuse symptoms (biopsies are required)
- Establishment of **biomarker pattern** to identify patients early in the disease to allow a **precision therapy** restore the mucosa and prevent further worsening of the condition

Partnering Strategy

- Looking for partner in the field of biomarker diagnostic
- Apply for external funding, national and EU
- IP protection (Marinosolv®) until 2036




Inhaleen (MAM-1000-1):

Highlights & strategy

- Inhalable formulation based on **iota-carrageenan**
- The **goal** is the prevention and therapy of **viral infections of the lung**
- It is expected that a combination of iota-carrageenan with an **antiviral drug** will result in an increased efficacy
- Already demonstrated with the **combination** of iota-carrageenan and **zanamivir** in an **influenza infection** model
- Currently the inhalation of iota-carrageenan is tested in **hospitalized COVID-19** patients in several clinics in Austria
- Treatment of viral respiratory infections caused by **major pathogenic viral families**
- **Substantial data package** already available for iota-carrageenan

Partnering Strategy


- Looking for an experienced partner to develop a broad-spectrum inhalable drug-device combination
- Available for in-licensing
- Classical license deal favored



Inhaleen (MAM-1000-1):

Broad-spectrum inhalable antiviral product combining at least two different mode of actions for optimal treatment of viral pneumonia

Efficacy of the combination of IC and zanamivir against influenza H7N7 in a lethal mouse infection model¹



Rationale for the use of iota-carrageenan (IC)

- Clinically proven to significantly reduce viral load¹
- Clinical effectiveness shown for human Rhinoviruses, Coronaviruses and Influenzaviruses²
- Synergistic efficacy in a mouse model shown for combination with the anti- influenza drug Zanamivir^{*,3}

Next steps

- Evaluate & identify antiviral combination with IC
- Carry out additional toxicology studies to enable early clinical study

Virus type	Virus-blocking activity demonstrated
SARS-CoV-2	X
SARS-CoV-1	X
Human coronavirus, endemic	X
Influenza A (human)	X
Influenza A (avian)	X
Influenza B	X
Parainfluenza virus	X
Respiratory syncytial virus	X
Human metapneumovirus	X
Human rhinovirus A and B	X
Human adenovirus	X

Antiviral inhibition by IC as shown in in vitro, in vivo or clinical studies³

¹Morokutti-Kurz et al., Int J General Medicine (2021);14: 5241

²Könighofer et al., Multidisciplinary Respiratory Medicine (2014); 9: 57

³Morokutti-Kurz et al., PLOS ONE (2015) | DOI:10.1371/journal.pone.0128794.

*Zanamivir is licensed for the treatment of uncomplicated influenza under the tradename Relenza

Budesolv (MAM-1004-1):

Highlights & strategy

- **Budesolv** is a Marinosolv®-based nasal spray of budesonide to treat allergic rhinitis
- Substantially improved **solubility** of API and thereby strongly increased bioavailability
- **Phase 3** clinical study successfully **completed**
- Dose reduced by >85% compared to the marketed product
- **Early onset of action shown**
- Licensed to a first development and marketing partner in **Greater China**
- **Further addressable indication** identified

Partnering Strategy

- Available for in-licensing outside China
- IP protection (Marinosolv®) until 2036
- Classical license deal favored




Flutisolv (MAM-1005-1):

Highlights & strategy

- **Flutisolv** is a Marinosolv®-based formulation of fluticasone propionate
- Substance well established in various indications characterized by an inflammation including allergic rhinitis, asthma, COPD, or atopic dermatitis
- Substantially improved **solubility** of API
- Strongly increased **bioavailability** shown in ex-vivo models
- Stability data indicate storage at room temperature is possible
- Phase 2/3 clinical study in the indication allergic rhinitis in evaluation

Partnering Strategy

- Available for partnering outside China
- IP protection (Marinosolv®) until 2036
- Classical license deal favored




Carravin (MAM-2001-1):

Product highlights & strategy

- A nasal spray combining the **virus-blocking** properties of **iota-carrageenan** and the decongestant properties of **xylometazoline**
- Currently **in registration process** in several European countries
- Product should provide **immediate relief** of the symptom blocked nose
- Data demonstrate that the two components are **not interfering**

Partnering Strategy

- Available for in-licensing
- Classical license deal favored



SOLV4U Technology partnerships

Marinosolv® solubilization technology to improve drug delivery and bioavailability

About Marinosolv®

- **Patent protected** drug delivery platform
- Based on **micelles** formed by excipients
- **Clinically validated** in phase 2 and 3 studies

Suitable for

- Hydrophobic **small molecules** and **peptides**
- **All stages** of NCE/API development
- **Re-formulation** and **re-purposing** of established APIs
- **Life cycle management** of APIs facing patent expiry
- Differentiation via **USFDA 505(b)(2) pathway**
- **Locally applied, locally acting** drugs for sensitive tissues
- **Systemic** administration routes

We offer


- Customized formulation development
- Feasibility studies
- Production of samples for early stage tox/PK studies
- Formulation optimization
- Upscale and tech transfer of manufacturing process




The technology: Marinosolv[®] works in two steps

Solubilization of water-insoluble compounds in a micelle forming aqueous system

Marinosolv formulation




Solubilization of API



Solv4U: Formulation development

Feasibility study and development of scalable manufacturing process



Carragelose

Expertise in **Virology** – brought to market

Mode of action



Virus enters mucosal cell



Barrier prevents internalization of virus

Carragelose forms a barrier on the nasal mucosa and unspecifically entraps viruses

Prophylactic and therapeutic efficacy clinically validated

Broadly active across several respiratory virus families and excellent safety profile

Partner Logos (sample)



Sanova
Advancing health



Product pictures (sample)



Disclaimer

This presentation (the “Presentation”) was prepared by Marinomed Biotech AG.

The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of this information or opinions contained herein. Neither Marinomed Biotech AG nor any officer or employee of Marinomed Biotech AG or any person connected with them accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this Presentation or its contents or otherwise arising in connection therewith. Marinomed Biotech AG undertakes no obligation to update or correct any information contained herein or to otherwise advise as to any future changes to it.

Certain statements contained in this document may be statements of future expectations and other forward looking statements that are based on management’s current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements.

Certain figures in this presentation have been rounded in accordance with commercial principles and practice. Such figures that have been rounded in various tables may not necessarily add up to the exact total given in the respective table.

This Presentation does not constitute or contain any investment advice. It is not and shall not be construed as an offer, invitation, recommendation or solicitation to sell, issue, purchase or subscribe for any securities in any jurisdiction or to enter into any transaction.

By accessing this Presentation, you represent, warrant and undertake that you have read and agree to comply with and to be bound by the contents of this disclaimer.



Marinomed Biotech AG

www.marinomed.com

